MBRX - Moleculin Biotech, Inc.
2.08
-0.160 -7.692%
Share volume: 178,604
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$2.24
-0.16
-0.07%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-10-2024 | 08-13-2024 | 11-08-2024 | 03-21-2025 | 05-13-2025 | 08-12-2025 | 11-13-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 6.645 M | 6.154 M | 7.104 M | 6.612 M | 5.912 M | 5.691 M | 5.885 M | |
| Selling general and admin | 2.393 M | 2.064 M | 2.172 M | 2.157 M | 2.477 M | 2.091 M | 2.147 M | |
| Research and development | 4.252 M | 4.090 M | 4.932 M | 4.455 M | 3.435 M | 3.600 M | 3.738 M | |
| Total expenses | 6.677 M | 6.185 M | 7.135 M | 6.644 M | 5.943 M | 5.720 M | 5.906 M | |
| -7.37% | 15.36% | -6.88% | -10.55% | -3.75% | 3.25% | |||
| Operating income | -6.677 M | -6.185 M | -7.135 M | -6.644 M | -5.943 M | -5.720 M | -5.906 M | |
| Ebit | -5.222 M | -4.489 M | -10.703 M | -1.942 M | -6.475 M | -7.670 M | -25.454 M | |
| Pretax income | -4.981 M | -4.330 M | -10.601 M | -1.894 M | -6.445 M | -7.644 M | -25.415 M | |
| -13.07% | 144.83% | -82.13% | 240.29% | 18.60% | 232.48% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -4.970 M | -4.319 M | -10.592 M | -1.882 M | -6.436 M | -7.640 M | -25.399 M | |
| 13.10% | -145.24% | 82.23% | -241.98% | -18.71% | -232.45% |